Forskning ved Københavns Universitet - Københavns Universitet

Forside

A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer

Publikation: Bidrag til tidsskriftTidsskriftartikel

  • Tine Thurison
  • Anne F Lomholt
  • Morten G Rasch
  • Ida K Lund
  • phw435, phw435
  • Ib J Christensen
  • Gunilla Høyer-Hansen
  • Anne Fog Lomholt
The liberated domain I of the urokinase plasminogen activator receptor [uPAR(I)] is a significant prognostic marker in lung and ovarian cancer, although the uPAR(I) concentration is below the limit of quantification (LOQ) in a substantial proportion of patient samples (Lung Cancer 2005;48:349-55; Clin Cancer Res 2008;14:5785-93; APMIS 2009;117:755-61). This study was undertaken to design an immunoassay with improved functional sensitivity for measuring uPAR(I) and to evaluate the prognostic value of uPAR(I) for colorectal cancer (CRC) patients.
OriginalsprogEngelsk
TidsskriftClinical Chemistry
Vol/bind56
Udgave nummer10
Sider (fra-til)1636-40
Antal sider5
ISSN0009-9147
DOI
StatusUdgivet - 1 okt. 2010

ID: 34090054